Abstract: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.

Abstract: To provide a peptide which can be produced and processed more readily compared with prothymosin ? , which is conventionally known, or a peptide thereof and has an activity at a level equivalent to or higher than that of prothymosin ? or a peptide thereof. The present invention provides an ameliorating agent for blood-organ barrier dysfunction, a therapeutic agent for diseases associated with blood-organ barrier dysfunction or ischemic diseases or a nerve cell death inhibitor, each comprising, as an active ingredient, a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or a peptide having substantially the same function as that of the aforementioned peptide.

Abstract: The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers.

Abstract: Disclosed are an rTRAIL mutant and monomethyl auristatin E (MMAE) conjugate thereof. The amino acid sequence thereof is as represented by SEQ ID No.1. Also disclosed are a coding gene of the rTRAIL mutant and expression system, recombinant vector and expression unit containing the coding gene. Also disclosed are an rTRAIL mutant-vcMMAE conjugate and preparation and uses thereof. The conjugate of the present invention has the biological functions of both the rTRAIL mutant and the MMAE; the MMAE is directionally transferred to a tumor cell through the specific binding between the rTRAIL mutant and a death receptor on the surface of the tumor cell, and is released and takes effect in the tumor cell, thus killing the tumor cells less sensitive or even resistant to TRAIL, and reducing the toxicity generated by the separate administration of the MMAE.

Abstract: The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

Abstract: Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.

Abstract: The present disclosure provides methods for producing expression constructs comprising linking a plurality of unlinked nucleic acids, including a nucleic acid encoding a marker protein.

Abstract: The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.

Abstract: A method of treating an angiogenesis related disease or disorder in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which regulates an amount of apolipoprotein B (ApoB), and/or an ability of ApoB to transcriptionally control vascular endothelial growth factor receptor 1 (VEGFR1).

Abstract: The present disclosure relates to a conformational specific antibody molecule recognizing a conformational epitope of human trimeric or tetrameric A? oligomers, wherein said antibody molecule does not bind human monomeric A? 1-42 or human Ap 1-42 dimers; and pharmaceutical and diagnostic compositions comprising said antibody molecule as well as methods using same.

Abstract: Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.

Abstract: The present disclosure encompasses novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.

Abstract: The present invention is an inducible coexpression system, capable of controlled induction of expression of each gene product.

Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.

Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.

Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

Abstract: The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (MMR) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics. Also, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are useful at different stages of cardiovascular diseases, including post-infarction cardiovascular events. Further, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are particularly useful for the in vivo targeting and/or imaging of vulnerable atherosclerotic plaques.

Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.

Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.

Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.

Abstract: A fusion protein including a targeting moiety, a cleavage site, and a cell membrane penetrating domain, a conjugate including the fusion protein and a bioactive molecule, and methods employing the fusion protein and the conjugate are provided.

Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.

Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

Abstract: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.

Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.

Abstract: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.

Abstract: The invention is a method for efficiently preparing alkali cellulose having a uniform alkali distribution therein. More specifically, the invention is a method for preparing alkali cellulose comprising steps of bringing pulp into continuous contact with an alkali metal hydroxide solution in a bucket conveyor type contactor to generate a contact mixture, and draining the contact mixture; a method for preparing a cellulose ether comprising use of the alkali cellulose thus prepared; and an apparatus for preparing alkali cellulose comprising a bucket conveyor contactor comprising at least one inlet port for introducing pulp and an alkali metal hydroxide solution at one end and at least one outlet port for discharging a contact mixture wherein the pulp and the alkali metal hydroxide solution can be moved from one end to the other end while bringing them into contact with each other to generate the contact mixture; and a drainer for separating a cake from the contact mixture discharged from the outlet port.

Abstract: An esterified cellulose ether which comprises (i) aliphatic monovalent acyl groups or (ii) groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, or (iii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, and which has a) a viscosity of from 1.2 to 1.8 mPaos, measured as a 2.0 wt % solution of the esterified cellulose ether in 0.43 wt % aqueous NaOH at 20° C., or b) a viscosity of up to 5 mPa·s, measured as a 10 wt % solution of the esterified cellulose ether in acetone at 20° C., or c) a combination of the viscosities of a) and b), is useful for preparing solid dispersions comprising drugs.

Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

Abstract: A method for protecting an electrical or electronic device against liquid damage, the method comprising a preliminary step of applying a continuous power plasma to the electrical or electronic device, followed by exposing the device to pulsed plasma comprising a compound of formula (I) where R1, R2 and R3 are independently selected from hydrogen, alkyl, haloalkyl or aryl optionally substituted by halo; and R4 is a group X—R5 where R5 is an alkyl or haloalkyl group and X is a bond; a group of formula C(O)O(CH2)nY where n is an integer of from 1 to 10 and Y is a bond or a sulphonamide group; or a group (O)pR6(O)q(CH2)t where R6 is aryl optionally substituted by halo, p is 0 or 1, q is 0 or 1 and t is 0 or an integer of from 1 to 10, provided that where q is 1, t is other than 0, for a sufficient period of time to allow a polymeric layer to form on the surface of the electrical or electronic device.

Abstract: Electropolymerizable compositions are disclosed. Certain electropolymerizable compositions include one or more 1,1-disubstituted alkene compounds and one or more conductive synergists. Other certain electropolymerizable compositions include one or more 1,1-disubstituted alkene compounds and one or more acid stabilizers and one or more free radical stabilizers.

Abstract: The present invention is directed to a process for the production of high density polyethylene by polymerisation of ethylene in the presence of a supported chromium oxide based catalyst which is modified with an organic compound comprising oxygen and a nitrogen atom which is selected from the group consisting of saturated heterocyclic organic compounds with a five or six membered ring, amino esters and amino alcohols. Such organic compounds allow manufacturing of HDPE with increases molecular weight distribution and increased molecular weight.

Abstract: A crosslinked polyethylene composition comprising 100 parts by weight of polyethylene, 0.05-5 parts by weight of crosslinking agent, 0.03-3 parts by weight of crosslinking aid. Polyethylene is a copolymer, homopolymer and/or a mixture thereof. The crosslinking agent is an organic peroxide having a half-life period longer than 3 minutes at 190° C. and/or a multi-membered heterocyclic alkane consisting of 3 to 6 carbon atoms and 3 to 6 oxygen atoms and/or a derivative thereof. The crosslinking aid is an organic substance containing allyl, maleimido, (meth)acrylate group and/or a polymer having a vinyl content higher than 50%. Preferably, the crosslinking aid is triallyl isocyanate (TAIC), triallyl cyanurate (TAC) or a mixture thereof. The crosslinked polyethylene composition has a crosslinking efficiency index >1000 Nm/g and a ? torque value >15 Nm at 220° C., and has a high safe processing temperature and long crosslinking delay, and therefore is particularly suitable for rotationally molded products.

Abstract: In accordance with the present disclosure, a method of preparing a solid support for a transition metal catalyst is disclosed. The solid support may have a unique morphology that may be derived from contacting the magnesium compound and an electron donor in the presence of a fluorinated organic compound to form the solid support. The solid support may be used to form an enhanced catalyst. The enhanced catalyst may be used, in combination with an organoaluminum compound, as a Ziegler-Natta (ZN) catalyst. The ZN catalyst including the enhanced catalyst may be used to form a UHMWPE.

Abstract: Techniques are provided for polymerization. A polymerization method may include polymerizing a monomer in a polymerization reactor to produce a slurry comprising polyolefin particles and a diluent, flowing the slurry out of the polymerization reactor through an outlet of the polymerization reactor, receiving the slurry from the outlet into a slurry handling system, conveying a first mixture from the slurry handling system to a diluent and monomer recovery system, and injecting steam into the first mixture downstream of the slurry handling system using a steam injection system.

Abstract: Perfluoro-t-butoxyallyl ether and perfluoro-t-butoxypropargyl ether and methods for their synthesis are disclosed. Also disclosed are methods for making polymers from the perfluoro-t-butoxyallyl ether and perfluoro-t-butoxypropargyl ether.

Abstract: Process for the preparation of (co) polymers of conjugated dienes which comprises polymerizing at least one conjugated diene in the presence of a catalytic system comprising at least one bis-imine complex of cobalt having general formula (I) wherein: —n is 0 or 1; —Y represents a group —CR?R?— wherein R? and R?, equal to or different from each other, represent a hydrogen atom; or a linear or branched C1-C20, preferably C1-C15, alkyl group; or a divalent aromatic group optionally substituted; —R1 and R2, equal to or different from each other, represent a hydrogen atom; or they are selected from a linear or branched Ci-C2o/preferably C1-C15, alkyl group optionally halogenated, cycloalkyl groups optionally substituted; or R1 and R2 can be optionally bound to each other to form, together with the other atoms to which they are bound, a cycle containing from 4 to 6 carbon atoms, saturated, unsaturated, or aromatic, optionally substituted with linear or branched C1-C20, preferably C1-C15, alkyl groups, said cycle op

Abstract: A modified polymer body 1 has a polymer body 2 composed of a polymer material containing a carbon-carbon double bond and first binding parts 3 and second binding parts 4 bound to the surface of the polymer body 2. The first binding parts 3 are such that an organic group 6 having a functional group is bound via an isocyanuric acid skeleton 5 to the surface of the polymer body 2. The second binding parts 4 are such that an organic group 7 having a functional group is directly bound to the surface of the polymer body 2 without interposing an isocyanuric acid skeleton 5.

Abstract: Group 4 transition metal complexes of bidentate iminonaphthol pro-ligands can be used as catalysts to polymerize olefins, such as ethylene. Group 4 transition metal complexes of bidentate iminonaphthol pro-ligands can have a single-site nature, allowing the catalysts to be used to prepare ultra high molecular weight polyethylene having a narrow molecular weight distribution.

Abstract: A method of making a low-fluoride reactive PIB composition includes (a) providing a modified C4 feedstock by way of blending a mixed C4 feedstock with a second feedstock having a lower LB/IsoB ratio; or providing a C4 feedstock with an LB/IsoB index of less than 10%; (b) feeding the modified C4 feedstock or the C4 feedstock with an LB/IsoB index of less than 10% to a CSTR with a homogeneous catalyst comprising BF3 and a modifier selected from alcohols, ethers and mixtures thereof; (c) polymerizing the modified C4 feedstock or the C4 feedstock with an LB/IsoB index of less than 10% in the reactor while maintaining the reactor at a temperature above ?15° C. and utilizing a residence time less than 45 minutes to produce a crude PIB composition in a polymerization mixture; and (d) recovering a purified PIB composition from the polymerization mixture having a molecular weight, Mn, from 250 to 5000 Daltons and an alpha vinylidene content of at least 50 mol %.

Abstract: The present invention relates to a method of preparing a vinyl chloride polymer having good thermal stability due to the restraint of dehydrochlorination by heat or ultraviolet rays, and a vinyl chloride polymer prepared thereby. In the preparation method, a modifier is introduced at the end of a polymerization process to impart the vinyl chloride polymer with high thermal stability without inducing modification. Therefore, the generation of dehydrochlorination due to heat or ultraviolet rays may be markedly restrained, thermal stability may be improved, and discoloration or the modification of physical properties may be prevented in the vinyl chloride polymer thus prepared.

Abstract: The present invention is directed to catalytic compositions and to curable compositions containing them. Catalytic compositions of the present invention typically comprise: (i) a reactive compound comprising at least one group selected from acid-functional groups and/or groups that may be converted to acid-functional groups; (ii) a metal compound; and (iii) a compound different from (i) and (ii) that catalyzes an addition reaction between an ethylenically unsaturated compound and a thiol. Curable compositions according to the present invention comprise: (a) a polyene, (b) a polythiol, and (c) the afore-mentioned catalytic composition.

Abstract: A method of making a low-fluoride reactive PIB composition includes in one embodiment: a) providing an isobutylene-enriched C4 feedstock by way of blending a first mixed C4 feedstock with a second feedstock having a lower LB/IsoB index; (b) feeding the isobutylene-enriched C4 feedstock to a polymerization reactor with a catalyst complex comprising BF3 and a modifier selected from alcohols, ethers and mixtures thereof; (c) polymerizing the isobutylene-enriched C4 feedstock in the reactor while maintaining the reactor at a temperature above ?40° C. and most preferably above ?15° C. and utilizing a residence time less than 45 minutes to produce a crude PIB composition in a polymerization mixture; and (d) recovering a purified PIB composition from the polymerization mixture having a molecular weight, Mn, from 250 to 5000 Daltons and an alpha vinylidene content of at least 50 mol %.

Abstract: The present invention provides an alkali-soluble resin having good developing performance, which belongs to the technical field of polymer material, so as to solve the problem of the poor developing performance of the current alkali-soluble resin and the photosensitive composition made of the same; and a method for preparing the same. In the present invention, tetrahydrofuran groups (flexible functional group) is introduced into the alkali-soluble resin by highly reactive unsaturated monomer, which can improve the developing property of the alkali-soluble resin and can produce a photoresist film with a smooth surface and no corrosion on its side wall.

Abstract: A method for polymerizing monomer units and/or oligomer units is disclosed. Said method is characterized in that the energy required for polymerization is introduced into the monomer units and/or oligomer units to be polymerized by means of infrared light pulses, wherein the infrared light pulses have a wavelength of 2500 to 20000 nm, an intensity of more than 1014 W/m2, a duration of more than 8 fs and less than 3 ps and a substantially linear polarization.

Abstract: The present invention relates to novel high-latency liquid hardeners for hardening of curable polymer resins, especially epoxy resins, and to epoxy resin compositions comprising liquid hardeners for the production of fiber composite materials.

Abstract: A polyurethane used for orthopedics external fixing system in complex environment is obtained by reaction of mixture of polyether polyol with modified isocyanate in the weight ratio of 1:0.6-0.75. The modified isocyanate is obtained by reaction of polyphenylene polymethylene isocyanate with polyether glycol. The components and corresponding weight percent amounts of the mixture of polyether polyol are as follows: 60-65% polyether polyol; 0.3-1% catalyst; 0.1-2% foam stabilizer; 0.1-2% or 3-20% foaming agent; 25-40% filler and 0.5-2% functional auxiliary agent. The method of producing the polyurethane is also provided.

Abstract: The invention relates to polyureas having a weight-average molecular weight ranging from 5,000 to 70,000 g/mol, the preparation thereof, and the use thereof as rheology control agents. The invention further relates to rheology control agents containing polyureas and to the use thereof. The invention moreover relates to formulations containing polyureas.

Abstract: A sulphur-comprising polyaromatic polyamine compound can be used as a monomer or prepolymer, when n is different from zero, in the synthesis of polyurea. The compound corresponds to the formula (I): H2N—Ar1—NH—CH2—CH(OH)—(CH2)m—O—Z1—O—(CH2)m—CH(OH)—CH2—[X]n—HN—Ar2—NH2 in which X represents the string: —HN—Ar3—NH—(CH2)—CH(OH)—(CH2)m—O—Z2—O—(CH2)m—CH(OH)—(CH2)— and in which n represents an integer equal to zero or different from zero; m, which are identical or different, represent an integer within a range from 1 to 10; Z1 and Z2, which are identical or different, represent a divalent bonding group comprising from 1 to 30 carbon atoms; and Ar1, Ar2 and Ar3, which are identical or different, each represent a phenylene group, at least one of these phenylene groups bearing one, two, three or four groups of formula —Sx—R in which “x” is an integer from 1 to 8 and R represents hydrogen or a hydrocarbon group which can comprise a heteroatom and which comprises from 1 to 10 carbon atoms.